Mayo Clinic Researchers Find Experimental Therapy Turns on Tumor Suppressor Gene in Cancer Cells

January 20, 2009

JACKSONVILLE, Fla. - Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say.

In the Feb. 15 issue of Cancer Research (available online Jan. 20), they report that RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. The agent is also known as CS-7017.

From previous research, the investigators knew that RS5444 binds to a protein known as PPAR-gamma, a transcriptional factor that increases the expression of many genes. They had found that human anaplastic thyroid tumor cells treated with RS5444 expressed a protein known as p21, which inhibited cell replication and tumor growth. But they did not understand how. They have now discovered that the agent actually forces PPAR-gamma to turn on the RhoB tumor suppressor gene, which in turn induces p21 expression.

"This is very unusual," says the study's lead investigator, John Copland, Ph.D., a cancer biologist at the Mayo Clinic campus at Jacksonville. "Drugs typically target genes and proteins that are over-expressed and turn them off. We found that RS5444 turns on a valuable tumor suppressor gene. We rarely find a drug that can take a suppressed gene and cause it to be re-expressed."

This finding suggests that other cancers in which RhoB is deactivated might respond to RS5444 or to similar drugs, says co-author Robert Smallridge, M.D., who treats thyroid cancer patients at Mayo Clinic in Jacksonville.

"This study provides a hint that this class of drugs could have a significant effect on cancer biology because of its action on this tumor suppressor gene," says Dr. Smallridge.

According to Dr. Copland, "RS5444 and other so-called PPAR-gamma drugs, which were originally created to treat diabetes because they help regulate glucose metabolism, are in development or being tested as cancer therapies. Taken orally, RS5444 requires 1,000-fold less dosage than current Food and Drug Administration-approved drugs in this class of compounds to inhibit tumor growth."

The researchers have been seeking to identify and characterize the molecular mechanisms underlying the cause and progression of human anaplastic thyroid carcinoma. Their goal is to develop effective molecular targeted therapies.

This cancer is extremely rare - fewer than 600 cases are diagnosed in the U.S. annually - but may be better known of late because it may have been the type of thyroid cancer that led to the death of William Rehnquist, chief justice of the United States. "It is also one of the most aggressive and deadliest known cancers, since it doesn't respond to any known treatment," says Dr. Smallridge. "The rate of survival hasn't changed in 25 years. Eighty-five percent of patients die within a year of diagnosis."

In previous work, the investigators identified a combination of drugs that reduced tumor size in animal models, strongly implicating that this regimen might benefit patients with the cancer. RS5444, developed by Daiichi Sankyo, Co., Ltd., in Japan, was one agent tested in combination with chemotherapy. Sankyo researchers discovered RS5444 in a screen for antitumor activity and then sought help from Mayo Clinic Cancer Center to further study its properties. Their encouraging findings in preclinical studies led to the launch of a multicenter Phase 1/2 clinical trial, testing use of RS5444 and paclitaxel chemotherapy in patients with the cancer. The study, led by Dr. Smallridge, is being conducted at Mayo Clinic campuses in Jacksonville and Rochester, Minn. and at eight other sites nationally.

Clinical Trial Information

This study was designed to look at the specific signaling pathways within anaplastic thyroid cancer cells that are disrupted by RS5444. Researchers had thought that because PPAR-gamma was mutated in a subset of thyroid cancers, PPAR-gamma might be acting as a tumor suppressor gene, and that turning it back on restored that function. This hypothesis made sense, because PPAR-gamma is a powerful nuclear receptor that activates genes involved in such cellular processes as differentiation, apoptosis, cell-cycle control, carcinogenesis, and inflammation.

But they found that PPAR-gamma regulates transcription of the RhoB gene. "Within several hours of administering the drug, we can see that it binds to the PPAR-gamma protein in cancer cells and activates RhoB transcription, causing expression of RhoB messenger RNA that is translated into protein. By a yet-to-be-identified mechanism, RhoB then induces the transcription of p21, thereby shutting down the cell cycle and blocking tumor growth," Dr. Copland says.

"That shows us that turning RhoB back on may be a key mechanism for regulating growth of this cancer," he says.

For proof, the researchers then turned off expression of RhoB in cells that were treated with the drug, and demonstrated that p21 could not be activated. "That shows RhoB is required for p21 transcription," Dr. Copland says.

"RhoB acts as a tumor suppressor, and it is turned off in anaplastic thyroid cancers. Turning this gene back on may lead to an effective molecular targeted chemotherapy regimen to fight this cancer," he says.

Dr. Smallridge adds, "Hitting this pathway inhibits tumor growth up to fourfold in laboratory cells and in animal experiments, and we are optimistic that it could be one cancer pathway capable of manipulation in patients. We hope there are other cancers in which RhoB is silenced, such as head and neck, brain, and lung cancers, that could benefit as well where RhoB has been shown to be down-regulated in patient tumor tissues."

Co-authors included researchers from Daiichi Sankyo, Co., Ltd., Eastern Virginia Medical School, and Mayo Clinic.

The study was funded by grants from the National Institutes of Health, Mayo Clinic Research Committee, the Florida Department of Health Bankhead Coley grant, and a grant for Rare Cancers from Dr. Ellis and Dona Brunton. Funding from the company is being used to conduct the clinical trial. Drs. Copland and Smallridge have a patent application pending on the use of molecular markers to confirm response to PPAR-gamma drugs.

Mayo Clinic

---

---

	Tumor Suppressor Genes: Volume 2: Regulation, Function, and Medicinal Applications (Methods in Molecular Biology) by Wafik S. El-Deiry (Editor) The second volume of Tumor Suppressor Genes explores the cell biology and biochemical function of the tumor suppressor genes, as well as its physiological role in vivo. The authors detail the physical methods (NMR, microarray approaches, pot-translational structure analysis, analysis of regulation at the gene expression and protein signaling levels)used to understand the function of tumor suppressor genes. In vivo approaches discussed include studies in yeast, Drosophilia, mice, and human tumors. For both volumes: Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or...
	Tumor Suppressor Genes by Katherine R. Polinsky (Editor) A tumour suppressor gene is a gene that reduces the probability that a cell in a multicellular organism will turn into a tumor cell. A mutation or deletion of such a gene will increase the probability of the formation of a tumor. Unlike oncogenes, tumor suppressor genes generally follow the 'two-hit hypothesis', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is due to the fact that if only one allele for the gene is damaged, the second can still produce the correct protein. However, there are cases where mutations in only one allele will cause an effect. A notable example is the gene that codes for p53. Tumor suppressor genes, or more precisely, the proteins for which they code, either have a dampening or repressive...
	Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development) by David E. Fisher (Editor) David Fisher, MD, PhD, and an authoritative panel of academic, cutting-edge researchers review and summarize the current state of the field. Describing the broad roles of tumor suppressors from a perspective based in molecular biology and genetics, the authors detail the major suppressors and the pathways they regulate, including cell cycle progression, stress responses, apoptosis, and responses to DNA damage. Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.
	The Oncogene & Tumour Suppressor Gene Factsbook, Second Edition by Robin Hesketh (Author) The Second Edition of The Oncogene and Tumour Suppressor Gene FactsBook has been completely revised, updated, and expanded by 60%. The book contains more than 80 entries on oncogenes including JUN, MYC, and RAS, as well as DNA tumour viruses, tumour suppressor genes, including p53, retinoblastoma, BRCA1, BRCA2, VHL, F2FL, and essential material on angiogenesis and metastasis, apoptosis, cell cycle control, and gene therapy. Key Features * Includes much new data on this fast-moving field, including newly discovered oncogenes * Summarizes the clinical association and molecular properties of all known oncogenes and tumor suppression genes * Contains more than 2000 terms for reference and further research * Revised to included...
	Oncogenes and Tumor Suppressor Genes in Human Malignancies (Cancer Treatment and Research) by C.C. Benz (Editor), E.T. Liu (Editor) This volume begins by reviewing selected malignancies in which the search for clinically relevant oncogenes has led to more focused studies on gain-of-function and loss-of-function genetic abnormalities, as well as autocrine and paracrine growth factor loops known to regulate tumor physiology and malignant cell behavior. Many of these genetic and functional abnormalities are shared by several different tumor types and are not uniformly present in all tumors of the same type. This observation brings up molecular questions about the tissue-specific determinants that underlie individual cancers and also gives added impetus to the suggestion that molecular abnormalities (referred to as tumor markers) be included among the histopathologic features used for clinical diagnosis and...
	Tumor Suppressor Genes (Immunology Series) by George Klein (Editor)
	Tumour Suppressor Genes, the Cell Cycle, and Cancer (Cancer Surveys) by A. J. Levine (Editor)
	Tumor Suppressor Genes: Volume 1: Pathways and Isolation Strategies (Methods in Molecular Biology) by Wafik S. El-Deiry (Editor) Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or sporadic cancers. They also provide a detailed guide to using powerful molecular genetic, cytogenetic, proteomic, and cell biological strategies to discover and isolate novel tumor suppressor genes and their targets. For both volumes: Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or sporadic cancers. They...
	Tumor Suppressor Genes in Breast Cancer by Marc Lacroix (Editor) Breast cancer is characterised by the accumulation of genetic alterations, including point mutations and loss of entire DNA regions ("loss of heterozygosity" or LOH). Among genes that are affected by such events, the "tumour suppresser genes" (TSGs) have a peculiar interest since they often occupy pivotal positions in regulatory networks that control the cell cycle and/or encompass various signal transduction cascades. While a number of genes have been suggested as candidate TSGs in breast cancer, only a few of them have been confirmed in this status. They include TP53, BRCA1, BRCA2 and are mainly involved in the control of DNA repair, cell proliferation, apoptosis and signalling. Some TSGs are linked to familial (hereditary) forms of breast cancer. The exact definition of what is a TSG...
	Oncogenes and Tumor Suppressor Genes (Medical Perspectives) by F. Macdonald (Author), C. H. J. Ford (Author)